Peripheral blood pDCs in stage I-III melanoma patients upregulated CCR6, a skin homing receptor, and were recruited to primary cutaneous melanoma lesions, in response to CCL20 produced in melanoma microenvironment [97]. Here, CCL20 is linked to melanoma.